Eyepoint Pharmaceuticals (EYPT) Expected to Announce Earnings on Wednesday

Eyepoint Pharmaceuticals (NASDAQ:EYPT) will likely be posting its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Eyepoint Pharmaceuticals to post earnings of ($0.77) per share and revenue of $3.3290 million for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 8:30 AM ET.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its earnings results on Wednesday, August 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.18). Eyepoint Pharmaceuticals had a negative return on equity of 63.80% and a negative net margin of 337.93%.The company had revenue of $5.33 million during the quarter, compared to analysts’ expectations of $6.82 million. On average, analysts expect Eyepoint Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Eyepoint Pharmaceuticals Trading Down 4.9%

Shares of EYPT stock opened at $12.45 on Tuesday. Eyepoint Pharmaceuticals has a 12-month low of $3.91 and a 12-month high of $14.91. The firm’s 50 day moving average is $12.85 and its 200 day moving average is $10.16. The stock has a market capitalization of $858.14 million, a P/E ratio of -4.65 and a beta of 1.95.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Mizuho set a $28.00 target price on shares of Eyepoint Pharmaceuticals in a report on Monday, October 20th. Chardan Capital reiterated a “buy” rating and set a $27.00 price target on shares of Eyepoint Pharmaceuticals in a research note on Thursday, August 7th. HC Wainwright lifted their price target on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, August 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.67.

Institutional Trading of Eyepoint Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of EYPT. Adage Capital Partners GP L.L.C. raised its position in shares of Eyepoint Pharmaceuticals by 9.7% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company’s stock valued at $63,988,000 after purchasing an additional 600,000 shares during the period. Corient Private Wealth LLC bought a new stake in Eyepoint Pharmaceuticals in the 2nd quarter valued at $1,200,000. Invesco Ltd. increased its holdings in Eyepoint Pharmaceuticals by 199.8% in the 2nd quarter. Invesco Ltd. now owns 128,772 shares of the company’s stock valued at $1,212,000 after acquiring an additional 85,824 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in Eyepoint Pharmaceuticals by 94.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 172,446 shares of the company’s stock valued at $1,623,000 after acquiring an additional 83,666 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in Eyepoint Pharmaceuticals by 8.5% in the 2nd quarter. Bank of America Corp DE now owns 814,153 shares of the company’s stock valued at $7,661,000 after acquiring an additional 63,941 shares during the last quarter. 99.41% of the stock is currently owned by institutional investors.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.